Todd Sherer, PhD
Chief Executive Officer of The Michael J. Fox Foundation for Parkinson’s Research
Todd Sherer, PhD, is the Chief Executive Officer of The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Formally trained as a neuroscientist, he directs the organization’s research strategy and is responsible for the organization’s overall scientific and fundraising direction to speed treatment breakthroughs and a cure for Parkinson’s disease. Dr. Sherer has been a key architect of the Foundation’s strategy to define high-priority research areas for Parkinson’s disease. He has played a major role in the Foundation’s efforts to increase the pharmaceutical industry’s investment in Parkinson’s disease drug development and engage the patient community to encourage and expand participation in clinical research. Dr. Sherer joined the Foundation’s staff full time in April 2004 and assumed the role of Chief Executive Officer in May 2011. He serves on the National Center for Advancing Translational Sciences Council and the Cures Acceleration Network Review Board at the National Institutes of Health. He is also on the coordinating committee for the Morris K. Udall Centers of Excellence in Parkinson’s Disease Research supported by the National Institute of Neurological Disorders and Stroke. Additionally, Dr. Sherer was selected to serve as a council member for the FasterCures’ TRAIN (The Research Acceleration and Innovation Network) program. Dr. Sherer has published more than 40 peer-reviewed articles and sits on the editorial board of the Journal of Parkinson’s Disease. He earned his PhD in Neuroscience from the University of Virginia in Charlottesville and holds a BS in Psychology from Duke University in Durham, North Carolina.
Melissa J. Nirenberg, MD, PhD
Chief Medical Officer of The New York Stem Cell Foundation
Melissa J. Nirenberg, MD, PhD is the Chief Medical Officer (CMO) of The New York Stem Cell Foundation (NYSCF), and an Adjunct Professor of Neurology at the NYU School of Medicine. She joined NYSCF as its inaugural CMO in September 2017. Dr. Nirenberg pursued her undergraduate education at Yale University, graduating magna cum laude with Distinction in English. She received her MD and a PhD in Neuroscience from the Tri-Insitutional MD-PhD program at Weill Cornell, where her doctoral research included investigation of the neuroanatomy of the dopamine-containing neurons that are affected in Parkinson’s disease and related disorders. She subsequently completed residency training in Neurology at the University of California, San Francisco, followed by a fellowship in Movement Disorders at Columbia University. In 2005, Dr. Nirenberg joined the faculty of Weill Cornell Medicine as an Assistant Professor of Neurology and Associate Director of the Division of Movement Disorders. While she was at Weill Cornell, she was also appointed Associate Director of the Tri-Institutional MD-PhD program. In 2012, Dr. Nirenberg joined NYU Langone Health as an Associate Professor of Neurology in the Division of Movement Disorders, where she was also Associate Director of the NYU Neurology Residency program.
Kevin Kalinsky, M.D., M.S
Assistant Professor of Medicine at the NewYork-Presbyterian Hospital/Columbia University Medical Center
Kevin Kalinsky, M.D., M.S. is an Assistant Professor of Medicine at the NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Kalinsky received his undergraduate B.A. from Emory University. He received his M.D. from the Medical University of South Carolina and completed his Internal Medicine internship and residency and Hematology/Oncology fellowship at Tufts Medical Center. In Boston, he also trained as a breast cancer clinical research fellow at Massachusetts General Hospital. In addition, he completed an advanced oncology fellowship in breast cancer at Memorial Sloan-Kettering Cancer Center. Since joining as a faculty member, Dr. Kalinsky completed a Master’s program in Biostatistics, Patient–Oriented Research at Columbia.
Dr. Kalinsky cares for patients diagnosed with breast cancer and teaches on the Breast Oncology service. He was recently awarded the Ewig Clinical Scholar Teaching Award at Columbia. Dr. Kalinsky’s research involves the development of early phase clinical trials to assess novel therapeutic agents in breast cancer based on tumor genomics. His work is funded by a number of sources, including the National Institute of Health and SWOG/Hope Foundation, and is a recipient of the 2017 NCI Cancer Clinical Investigator Team Leadership Award.
Michael Kolodziej M.D.
Vice President and Chief Innovation Officer, ADVI Health
Michael Kolodziej M.D. is Vice President and Chief Innovation Officer, ADVI Health. Dr. Kolodziej attended college and medical school at Washington University in St. Louis where he was Phi Beta Kappa and Alpha Omega Alpha. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, Dr. Kolodziej joined the faculty at the University of Oklahoma School of Medicine where he was an associate professor. He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics committee, on the executive committee from 2002-2011, and chairman from 2004-2011. He served as Medical Director for Oncology Services for US Oncology from 2007-2011. In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology. He joined Aetna in January, 2013 as National Medical Director, Oncology Solutions. While at Aetna, he directed Aetna’s oncology delivery reform pilots and was the architect of the Aetna Oncology Medical Home program. He was also active in Aetna’s pharmacy policy, condition analysis, and genetics subcommittees. Dr. Kolodziej joined Flatiron Health in July, 2016 as National Medical Director, Managed Care Strategy where he applied the core tech and data capabilities of Flatiron to facilitate practice transformation and success in alternative payment models. He joined ADVI in October, 2017. He is a Fellow of the American College of Physicians. He has published and spoken extensively on payment reform, personalized medicine, and practice care delivery transformation in oncology.
Annette Bakker, Ph.D.
President and Chief Scientific Officer, the Children’s Tumor Foundation
Annette Bakker, PhD, is the current President and Chief Scientific Officer of the Children’s Tumor Foundation, a non-profit that works to drive research, expand knowledge, and advance care for the neurofibromatosis (NF) community. She is directly responsible for managing the Foundation’s research, fundraising, outreach, and development operations, and has greatly expanded the Foundation’s research programs. She has served as the oncology head for a biotech company in Siena, Tuscany, where she built their oncology program from the ground up, and managed their neuro and oncology research initiatives throughout Europe and Asia. She has extensive experience acting as a liaison for pharmaceutical and biotech companies, and her research has been recognized internationally through peer-reviewed papers, awards, and patents. She was most recently the recipient of a 2017 RARE Champion of Hope Award for her notable efforts in science, presented by the rare disease patient advocacy organization, Global Genes. She is also a lecturer at the University of Alabama at Birmingham, and was a former oncology group leader at Janssen Pharmaceuticals in Belgium. She received her PhD in Cell Biology from the University of Antwerp, and completed postdoctoral fellowships at Yale University and La Salpetriere, Paris.
Global Head of Janssen Diagnostics
Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.
In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.
Founder and CEO of Alva10
Hannah Mamuszka is the Founder and CEO of Alva10, a company focused on driving up the value of diagnostics in healthcare. Ms Mamuszka founded Alva10 after having spent almost 20 years in the Cambridge, MA biotech community, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda).
Diagnostics are the key to Precision Medicine, but they need to be valued in the healthcare market in order to be successful. For years, diagnostics have been stuck in a downward cycle of value, with poor reimbursement leading to lack of investment, and lack of investment leading to sub-optimal clinical validation, leading back to poor reimbursement. Alva10 is changing that, bringing diagnostics to the forefront of Precision Medicine by partnering with payers and diagnostics companies using a proprietary algorithm to determine economic impact of diagnostics and create a new value based healthcare model.
Emanuel Petricoin III, PhD
University Professor, Co-Director Center for Applied Proteomics and Molecular Medicine, George Mason University
Dr. Emanuel F Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program and a Senior Investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. Dr. Petricoin received his PhD in Microbiology from the University of Maryland in 1990. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, molecular diagnostics and biomarker discovery. He is a co-founder of 4 life science companies, including 2 precision medicine companies: Theranostics Health, Inc. and Perthera, Inc. located in McClean VA, where is a co-founder and Chief Science Officer. He is a co-inventor on 40 filed and published patents, and has authored over 360 peer-reviewed publications and invited reviews. He has authored over 45 book chapters, is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, Carcinogenesis, Journal of Personalized Medicine and Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO). He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award and is s Kentucky Colonel. He is the faculty representative to the George Mason University Research Foundation.
Dr. George Poste
Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University
Dr. Poste is currently the Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University. This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine.
He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences and Scientific Advisory Boards at the University of Michigan, Synthetic Genomics and Haplogen GmbH.
He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and U.K. Academy of Medicine, Member, Council for Foreign Relations, and Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.